Despite the failure of early clinical trials, a large body of evidence from animal and genetic studies supports the hypothesis that CETP inhibition is antiatherogenic, necessitating the completion of ongoing trials.
Originally published August 3, 2015. Response to Barter et al. by G. Kees Hovingh, Kausik K. Ray, S. Matthijs Boekholdt on pg. 432
Barter et al. (Mon,) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). CETP inhibitors was evaluated. Despite the failure of early clinical trials, a large body of evidence from animal and genetic studies supports the hypothesis that CETP inhibition is antiatherogenic, necessitating the completion of ongoing trials.